Cargando…
Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases
The NLRP3 inflammasome’s core and most specific protein, NLRP3, has a variety of functions in inflammation-driven diseases. Costunolide (COS) is the major active ingredient of the traditional Chinese medicinal herb Saussurea lappa and has anti-inflammatory activity, but the principal mechanism and m...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978959/ https://www.ncbi.nlm.nih.gov/pubmed/36873170 http://dx.doi.org/10.1016/j.apsb.2022.09.014 |
_version_ | 1784899634807701504 |
---|---|
author | Xu, Haowen Chen, Jiahao Chen, Pan Li, Weifeng Shao, Jingjing Hong, Shanshan Wang, Yi Chen, Lingfeng Luo, Wu Liang, Guang |
author_facet | Xu, Haowen Chen, Jiahao Chen, Pan Li, Weifeng Shao, Jingjing Hong, Shanshan Wang, Yi Chen, Lingfeng Luo, Wu Liang, Guang |
author_sort | Xu, Haowen |
collection | PubMed |
description | The NLRP3 inflammasome’s core and most specific protein, NLRP3, has a variety of functions in inflammation-driven diseases. Costunolide (COS) is the major active ingredient of the traditional Chinese medicinal herb Saussurea lappa and has anti-inflammatory activity, but the principal mechanism and molecular target of COS remain unclear. Here, we show that COS covalently binds to cysteine 598 in NACHT domain of NLRP3, altering the ATPase activity and assembly of NLRP3 inflammasome. We declare COS’s great anti-inflammasome efficacy in macrophages and disease models of gouty arthritis and ulcerative colitis via inhibiting NLRP3 inflammasome activation. We also reveal that the α-methylene-γ-butyrolactone motif in sesquiterpene lactone is the certain active group in inhibiting NLRP3 activation. Taken together, NLRP3 is identified as a direct target of COS for its anti-inflammasome activity. COS, especially the α-methylene-γ-butyrolactone motif in COS structure, might be used to design and produce novel NLRP3 inhibitors as a lead compound. |
format | Online Article Text |
id | pubmed-9978959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-99789592023-03-03 Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases Xu, Haowen Chen, Jiahao Chen, Pan Li, Weifeng Shao, Jingjing Hong, Shanshan Wang, Yi Chen, Lingfeng Luo, Wu Liang, Guang Acta Pharm Sin B Original Article The NLRP3 inflammasome’s core and most specific protein, NLRP3, has a variety of functions in inflammation-driven diseases. Costunolide (COS) is the major active ingredient of the traditional Chinese medicinal herb Saussurea lappa and has anti-inflammatory activity, but the principal mechanism and molecular target of COS remain unclear. Here, we show that COS covalently binds to cysteine 598 in NACHT domain of NLRP3, altering the ATPase activity and assembly of NLRP3 inflammasome. We declare COS’s great anti-inflammasome efficacy in macrophages and disease models of gouty arthritis and ulcerative colitis via inhibiting NLRP3 inflammasome activation. We also reveal that the α-methylene-γ-butyrolactone motif in sesquiterpene lactone is the certain active group in inhibiting NLRP3 activation. Taken together, NLRP3 is identified as a direct target of COS for its anti-inflammasome activity. COS, especially the α-methylene-γ-butyrolactone motif in COS structure, might be used to design and produce novel NLRP3 inhibitors as a lead compound. Elsevier 2023-02 2022-09-25 /pmc/articles/PMC9978959/ /pubmed/36873170 http://dx.doi.org/10.1016/j.apsb.2022.09.014 Text en © 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Xu, Haowen Chen, Jiahao Chen, Pan Li, Weifeng Shao, Jingjing Hong, Shanshan Wang, Yi Chen, Lingfeng Luo, Wu Liang, Guang Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases |
title | Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases |
title_full | Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases |
title_fullStr | Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases |
title_full_unstemmed | Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases |
title_short | Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases |
title_sort | costunolide covalently targets nacht domain of nlrp3 to inhibit inflammasome activation and alleviate nlrp3-driven inflammatory diseases |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978959/ https://www.ncbi.nlm.nih.gov/pubmed/36873170 http://dx.doi.org/10.1016/j.apsb.2022.09.014 |
work_keys_str_mv | AT xuhaowen costunolidecovalentlytargetsnachtdomainofnlrp3toinhibitinflammasomeactivationandalleviatenlrp3driveninflammatorydiseases AT chenjiahao costunolidecovalentlytargetsnachtdomainofnlrp3toinhibitinflammasomeactivationandalleviatenlrp3driveninflammatorydiseases AT chenpan costunolidecovalentlytargetsnachtdomainofnlrp3toinhibitinflammasomeactivationandalleviatenlrp3driveninflammatorydiseases AT liweifeng costunolidecovalentlytargetsnachtdomainofnlrp3toinhibitinflammasomeactivationandalleviatenlrp3driveninflammatorydiseases AT shaojingjing costunolidecovalentlytargetsnachtdomainofnlrp3toinhibitinflammasomeactivationandalleviatenlrp3driveninflammatorydiseases AT hongshanshan costunolidecovalentlytargetsnachtdomainofnlrp3toinhibitinflammasomeactivationandalleviatenlrp3driveninflammatorydiseases AT wangyi costunolidecovalentlytargetsnachtdomainofnlrp3toinhibitinflammasomeactivationandalleviatenlrp3driveninflammatorydiseases AT chenlingfeng costunolidecovalentlytargetsnachtdomainofnlrp3toinhibitinflammasomeactivationandalleviatenlrp3driveninflammatorydiseases AT luowu costunolidecovalentlytargetsnachtdomainofnlrp3toinhibitinflammasomeactivationandalleviatenlrp3driveninflammatorydiseases AT liangguang costunolidecovalentlytargetsnachtdomainofnlrp3toinhibitinflammasomeactivationandalleviatenlrp3driveninflammatorydiseases |